Resumen
The consortium proposes a new and novel therapeutic approach for the treatment of osteoarthritis through a miRNA-based therapy, one of the most innovative and successful strategies for the modulation of gene expression. This being a therapeutic solution that seeks to develop a "small molecule" and not an "Advanced Therapy Medicinal Product" (ATMP). Specifically, these are chemically engineered oligonucleotides that silence endogenous microRNAs by preventing their binding to a specific mRNA molecule, termed antimiR. Specifically, the therapy proposed here is based on the inhibition by antimiR of the microRNAs that repress SOST, thus increasing the expression of these genes, in such a way as to protect against cartilage degradation and loss of articular chondrocyte cellular proteoglycans, which are present in people suffering from osteoarthritis.
